<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162146">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00987688</url>
  </required_header>
  <id_info>
    <org_study_id>DJC003</org_study_id>
    <nct_id>NCT00987688</nct_id>
  </id_info>
  <brief_title>The Prophylactic Hypothermia Trial to Lessen Traumatic Brain Injury</brief_title>
  <acronym>POLAR-RCT</acronym>
  <official_title>Multi-centre Randomised Trial to Evaluate the Effect of Early Hypothermia on Neurological Function in Patients With Severe Traumatic Brain Injury. Including Renal Sub Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Australian and New Zealand Intensive Care Research Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Australian and New Zealand Intensive Care Society Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Health and Medical Research Council, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Transport Accident Commision, Victoria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Délégation à la Recherche Clinique et à l'Innovation (DRCI) CHU Besançon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Australian and New Zealand Intensive Care Research Centre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is a leading cause of death and long term disability,
      particularly in young adults. Studies from Australia have shown that approximately half of
      those with severe traumatic brain injury will be severely disabled or dead 6 months post
      injury. Given the young age of many patients with severe TBI and the long term prevalence of
      major disability, the economic and more importantly the social cost to the community is very
      high.

      Pre-hospital and hospital management of patients with severe brain injury focuses on
      prevention of additional injury due primarily to lack of oxygen and insufficient blood
      pressure. This includes optimising sedation and ventilation, maintaining the fluid balance
      and draining Cerebrospinal Fluid (CSF) and performing surgery where appropriate. In recent
      years there has been a research focus on specific pharmacologic interventions, however, to
      date, there has been no treatment that has been associated with improvement of neurological
      outcomes.

      One treatment that shows promise is the application of hypothermia (cooling). This treatment
      is commonly used in Australia to decrease brain injury in patients with brain injury
      following out-of-hospital cardiac arrest. Cooling is thought to protect the brain using a
      number of mechanisms. There have been a number of animal studies that have looked at how
      cooling is protective and also some clinical research that suggests some benefit. However at
      the current time there is insufficient evidence to provide enough proof that cooling should
      be used routinely for patients with brain injury and like all treatments there can be some
      risks and side effects.

      The POLAR trial has been developed to investigate whether early cooling of patients with
      severe traumatic brain injury is associated with better outcomes. It is a randomised
      controlled trial, which is a type of trial that provides the highest quality of evidence.

      The null hypothesis is that there is no difference in the proportion of favourable
      neurological outcomes six months after severe traumatic brain injury in patients treated
      with early and sustained hypothermia, compared to standard normothermic management.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of favourable neurological outcomes (Glasgow Outcome Score Extended: GOSE 5 to 8)</measure>
    <time_frame>6 months post injury</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessments *SF-12 (version 1) *EQ5D</measure>
    <time_frame>6 months post injury</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality (all cause)</measure>
    <time_frame>6 months post injury</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of favourable (GOSE 5-8) neurological outcomes in survivors</measure>
    <time_frame>6 months post injury</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events *Significant bleeding - assessed clinically *Infection - assessed clinically</measure>
    <time_frame>During the study intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative proportion of patients with Acute Kidney Injury (Injury/Failure Risk Injury Failure Loss End stage (RIFLE) categories) in those receiving cooling v. normothermia</measure>
    <time_frame>Day 7 of hospital admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of biomarkers neutrophil gelatinase-associated lipocalin (NGAL), cystatin C and liver-type fatty acid binding protein (L-FABP) will be measured in plasma and urine from blood and urine specimens obtained from 50 patients.</measure>
    <time_frame>24hrs, 48 hrs, 72 hrs post Intensive Care admission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economic Evaluation</measure>
    <time_frame>6 months post injury</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to reach 33C and dichotomised GOSE scores</measure>
    <time_frame>6 months post injury</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Brain Injury</condition>
  <arm_group>
    <arm_group_label>Hypothermia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early and sustained hypothermia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normothermia</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard management</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hypothermia</intervention_name>
    <description>exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C 3 days. Rewarming will occur at a rate of 0.17C/hr and will be titrated to intracranial pressure (ICP) control and BP.</description>
    <arm_group_label>Hypothermia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Blunt trauma with clinical diagnosis of severe TBI and GCS &lt;9

          -  Estimated age ≥ 18 and &lt; 60 years of age

          -  The patient is intubated or intubation is imminent

        Exclusion Criteria:

          -  Pre-hospital:

               -  Clinical diagnosis of drug or alcohol intoxication as predominant cause of coma

               -  Randomisation unable to be performed within 3 hrs of estimated time of injury

               -  Able to be intubated without drugs

               -  Systolic BP &lt;90mmHg

               -  Heart rate &gt; 120bpm

               -  GCS=3 + un-reactive pupils

               -  Penetrating neck/torso injury

               -  Known or obvious pregnancy

               -  Receiving hospital is not a study site

               -  Evidence of current anti-coagulant treatment

          -  Emergency Dept:

               -  Clinical diagnosis of drug or alcohol intoxication as predominant cause of coma

               -  Randomisation unable to be performed within 3 hrs of estimated time of injury

               -  Able to be intubated without drugs

               -  GCS=3 + un-reactive pupils

               -  Persistent Systolic BP &lt;90mmHg

               -  Clinically significant bleeding likely to require haemostatic intervention, for
                  example:

                    -  Bleeding into the chest, abdomen or retro-peritoneum likely to require
                       surgery +/- embolisation

                    -  Pelvic fracture likely to require surgery +/- embolisation

                    -  More than two long bone fractures requiring operative fixation

               -  Penetrating neck/torso injury

               -  Positive urine or blood pregnancy test

               -  Evidence of current anti-coagulant treatment

               -  In the treating clinician's opinion, &quot;cooling&quot; is not in the patient's best
                  interest
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie Cooper, BMBS, MD</last_name>
    <role>Study Chair</role>
    <affiliation>ANZIC RC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tony V Trapani, BEd BEmH RN</last_name>
    <phone>+61 409 798 892</phone>
    <email>tony.trapani@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lynne Murray</last_name>
    <phone>+61 419 155 983</phone>
    <email>Lynnette.Murray@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Meyer</last_name>
      <email>Jason.Meyer@health.qld.gov.au</email>
    </contact>
    <investigator>
      <last_name>Chris Joyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Gold Coast</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>: 07 568 74149</phone>
      <email>Elizabeth.Wake@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <email>Martin.Wullschleger@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Martin Wullschleger, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Barge</last_name>
      <email>Deborah.Barge@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Chris Macisaac, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Vallance, RN</last_name>
      <email>s.vallance@alfred.org.au</email>
    </contact>
    <investigator>
      <last_name>David J Cooper, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Waterson</last_name>
      <email>Sharon.Waterson@health.wa.gov.au</email>
    </contact>
    <investigator>
      <last_name>Steve Webb, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jean Minjoz Hospital</name>
      <address>
        <city>Besancon</city>
        <state>Franche Comte</state>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Vettoretti</last_name>
      <email>lvettoretti@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Sebastien Pilifloury, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>de La Cavale Blanche Hospital</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Dias</last_name>
      <email>patricia.dias@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier Huet, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabriel Montpied Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Vettoretti</last_name>
      <email>lvettoretti@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Russell Chabanne, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>de Hautepierre Hospital</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Vettoretti</last_name>
      <email>lvettoretti@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Michael Lorich, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Auckland DCCM</name>
      <address>
        <city>Auckland</city>
        <state>North Island</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynette Newby</last_name>
      <email>LynetteN@adhb.govt.nz</email>
    </contact>
    <investigator>
      <last_name>Colin McArthur, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waikato District Health Board</name>
      <address>
        <city>Waikato</city>
        <state>North Island</state>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Bern University Hospital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Roth</last_name>
      <email>Marianne.Roth@insel.ch</email>
    </contact>
    <contact_backup>
      <email>Matthias.Haenggi@insel.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Matthais Haenggi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>New Zealand</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Nichol A, Gantner D, Presneill J, Murray L, Trapani T, Bernard S, Cameron P, Capellier G, Forbes A, McArthur C, Newby L, Rashford S, Rosenfeld JV, Smith T, Stephenson M, Varma D, Walker T, Webb S, Cooper DJ. Protocol for a multicentre randomised controlled trial of early and sustained prophylactic hypothermia in the management of traumatic brain injury. Crit Care Resusc. 2015 Jun;17(2):92-100.</citation>
    <PMID>26017126</PMID>
  </reference>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 30, 2016</lastchanged_date>
  <firstreceived_date>September 29, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Australian and New Zealand Intensive Care Research Centre</investigator_affiliation>
    <investigator_full_name>David James Cooper</investigator_full_name>
    <investigator_title>Director, ANZIC rc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
